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in mortality rate. However, spontaneous MI was signifi-
cantly more common in the group receiving immediate PCI 
(11.0 vs. 1.4 %; HR 4.46, 95 % CI: 1.21–16.50, p = 0.02). We 
did not find a significant difference between the groups with 
respect to re-PCI rate.
Conclusion There was no difference in the composite of 
death and spontaneous MI. The trial suggests an increased 
long-term risk of spontaneous MI for patients treated with 
immediate PCI.
Keywords NSTE-ACS · Timing of PCI · Long-term 
outcomes
Introduction
The optimal timing when using percutaneous interven-
tion (PCI) in a non-ST-elevation acute coronary syndrome 
(NSTE-ACS) is still a matter of much debate. Early inter-
vention may be beneficial in patients with NSTE-ACS as 
it could prevent a new myocardial infarction (MI). On the 
other hand, it could prove more harmful as it might lead to an 
increased incidence of periprocedural complications due to 
the thrombotic tendency of the culprit lesion. First-line med-
ical pacification of the culprit coronary plaque may be bene-
ficial but it requires time, during which a recurrent infarction 
may occur. The current guidelines recommend urgent (ESC 
guidelines definition: < 2 h) coronary angiography in patients 
with a very high risk, defined as: refractory angina, with 
associated heart failure, life-threatening ventricular arrhyth-
mias, or haemodynamic instability. In addition, early (ESC 
guidelines definition: < 24 h) coronary angiography is rec-
ommended in patients with a GRACE risk score above 140 
or with high-risk features, defined as a relevant rise or fall in 
troponin or dynamic ST or T-wave changes [1, 2].
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Abstract
Background The OPTIMA trial was a randomised multi-
centre trial exploring the influence of the timing of percuta-
neous coronary intervention (PCI) on patient outcomes in an 
intermediate to high risk non-ST-elevation acute coronary 
syndrome (NSTE-ACS) population. In order to decide the 
best treatment strategy for patients presenting with NSTE-
ACS, long-term outcomes are essential.
Methods Five-year follow-up data from 133 of the 142 pa-
tients could be retrieved (94 %). The primary endpoint was 
a composite of death and spontaneous myocardial infarction 
(MI). Spontaneous MI was defined as MI occurring more 
than 30 days after randomisation. Secondary endpoints were 
the individual outcomes of death, spontaneous MI or re-PCI.
Results No significant difference with respect to the prima-
ry endpoint was observed (17.8 vs. 10.1 %; HR 1.55, 95 % 
CI: 0.73–4.22, p = 0.21). There was no significant difference 
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bundle branch block (LBBB), development of pathological Q 
waves on the ECG, imaging evidence of new loss of viable 
myocardium or new regional wall motion abnormality.
Statistical analysis
The analysis was based on the intention to treat. Cumula-
tive event rates were estimated using the Kaplan-Meier 
method. Hazard ratios (HRs) with 95 % confidence intervals 
(CIs) were obtained with Cox proportional hazards models 
and included the treatment strategy as the only covariate. 
Pre-specified subgroup analyses included gender, smoking, 
hypertension and diabetes. The GRACE RISK score was cal-
culated for stratification purposes in all patients. Statistical 
analyses were applied using the Statistical Package for Social 
Sciences (SPSS version 15.0 for Windows, Chicago, Illinois).
Results
From March 2005 until April 2007, 251 patients were enrolled 
in the OPTIMA trial. After undergoing immediate angiogra-
phy, a culprit lesion amenable to PCI was identified in 142 
patients. Patients were not randomised when angiography 
did not demonstrate significant coronary stenosis amenable 
for PCI, when coronary artery bypass grafting (CABG) was 
judged to be the preferred treatment, when the culprit lesion 
was instent restenosis or if the affected myocardial territory 
involved a chronic occlusion. These patients were treated 
according to institutional practices. The study randomised the 
patients amenable to PCI to an immediate (n = 73) or deferred 
(n = 69) coronary intervention. Table 1 shows the baseline 
characteristics, which were similar in the two groups, except 
for more previous CABG in the immediate group (11 vs. 1 %, 
p = 0.02) and the increased prevalence of hypertension in the 
immediate group (53 vs. 33 %, p = 0.03). The results of 30-day 
and 6-month follow-up were published previously [3] in which 
74 (52 %) of the 142 patients showed multivessel disease. Of 
these, 26 % underwent treatment of two or more lesions lead-
ing to complete revascularisation in 74 % of the total number 
of patients. Treatment characteristics were equally distributed 
between the groups. Pharmacological treatment regimens 
were similar in both groups with over 95 % receiving aspirin 
and clopidogrel. Furthermore, the use of β-blocking agents 
and statins was high, indicating optimal medical treatment. 
For the complete lists of medication at admission we refer to 
the 30-day follow-up article [3]. The original study showed 
an increased rate of periprocedural MI in patients treated with 
immediate PCI as compared with patients with a PCI deferred 
for 24–48 h. Five-year follow-up data from 133 of the 142 
patients could be retrieved (94 %). Three patients were lost to 
follow-up in the immediate group and six patients were lost to 
follow-up in the deferred group (Fig. 1).
The optimal timing of angiography and revascularisa-
tion in NSTE-ACS has been studied quite extensively. Yet 
the influence of the timing on PCI remains less clear due 
to the fact that previous trials chose to randomise the tim-
ing of the coronary angiography. The OPTIMA trial ran-
domised patients with a suspected NSTEMI into immediate 
or delayed PCI after their eligibility had been established by 
acute coronary angiography [3].
In contrast to trials comparing routine versus selective 
invasive intervention, no long-term data from trials evalu-
ating optimal timing of angiography have been published. 
Results of trials investigating routine versus selective inva-
sive intervention in NSTE-ACS suggest that spontaneous 
MI in contrast to periprocedural MI increases long-term 
mortality [4–6]. Long-term outcomes should be known in 
order to decide the proper treatment strategy for patients 
presenting with NSTE-ACS.
In the current study, the 5-year clinical outcomes of death, 
MI and revascularisation of the OPTIMA trial are reported.
Materials and methods
Study design
The original study design and the results have been pub-
lished previously [3] and the protocol was approved by the 
review board of all the participating centres. All patients 
gave informed consent.
The OPTIMA trial was a randomised multicentre trial 
exploring the influence of the timing of PCI on patient out-
comes in an intermediate to high risk NSTE-ACS popula-
tion. Follow-up was done on all the patients who had given 
their informed consent in the original OPTIMA trial. In 
cases where no information regarding the patient’s vital sta-
tus or above-mentioned endpoints at 5-year follow-up could 
be retrieved from the patient file, the general practitioner 
and/or the local authorities were contacted. After it had been 
confirmed that the patient was still alive, the patient was 
contacted by telephone.
Outcomes
The main outcome in the analysis was the combined endpoint 
of death and spontaneous MI. The secondary endpoints were 
the individual outcomes of death, spontaneous MI or re-PCI. 
Spontaneous MI was defined as: MI occurring more than 30 
days after randomisation. The universal definition for MI was 
used [7]. The definition includes the detection of a rise and/
or fall of troponin T with at least one value above the 99th 
percentile upper reference limit and with at least one of the 
following: symptoms of ischaemia, new or presumed new 
significant ST-segment–T wave (ST–T) changes or new left 
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difference was irrespective of initial procedure-related myo-
cardial infarction (Table 2). A sub-group analysis showed 
that most of the spontaneous MIs occurred in the index ves-
sel (Table 3). There were no significant differences in the 
re-PCI rate at 5-year follow-up between the immediate and 
deferred group. The re-PCI rate was 6.8 % in the immediate 
group and 11.6 % in the deferred group (HR 0.53 95 % CI: 
0.18–1.59, p = 0.26).
Discussion
After 5 years, no differences appeared in the composite 
endpoint of death and spontaneous MI between the groups. 
However, the long-term follow-up of the OPTIMA trial sug-
gests an increased risk of a spontaneous MI in those patients 
treated with an immediate PCI for their index NSTE-ACS. 
The pathophysiology behind this excess of spontaneous MI 
is most likely multifactorial.
Five-year follow-up
No significant difference was found between the immedi-
ate and the deferred group with respect to the composite 
endpoint of death or spontaneous MI (17.8 vs 10.1 %; HR 
1.55, 95 % CI: 0.73–4.22, p = 0.21). Mortality at 5 years was 
8.22 % in the immediate group and 8.70 % in the deferred 
group (HR 0.90, 95 % CI: 0.29–2.80, p = 0.86, Fig. 2).
However, a significant difference was found with respect 
to spontaneous MI at 5-year follow-up. In total, 8 patients 
in the immediate group and 1 patient in the deferred group 
experienced a spontaneous MI (11.0 and 1.4 %; HR 4.46, 
95 % CI: 1.21–16.50, p = 0.02, Fig. 3). Since these events 
occurred at least 30 days after the index hospitalisation, this 
Table 1 Baseline and patient characteristics
Characteristics Immediate 
PCI (n = 73)
Deferred 
PCI (n = 69)
p-value
Demographics
Male sex 51 (70) 51 (74) 0.6
Age (years), mean (SD) 63 (12) 62 (12) 0.8
Risk factors 41 (56) 34 (49) 0.4
Age > 60 years
Known CAD 27 (37) 25 (36) 0.6
Diabetes mellitus 14 (19) 14 (20) 1.0
Hypertension 39 (53) 23 (33) 0.03
Smoking 28 (38) 27 (39) 0.8
Family history of IHD 32 (44) 29 (42) 0.8
Hyperlipidaemia 28 (38) 22 (32) 0.6
Peripheral artery disease 5 (7) 3 (4) 0.7
Cardiac history
Previous MI 15 (21) 18 (26) 0.5
Previous PCI 20 (27) 13 (19) 0.2
Previous CABG 8 (11) 1 (1) 0.02
Previous CHF 1 (1) 1 (1) 0.3
GRACE-risk score
≤ 140 59 (81) 54 (78) 0.7
> 140 14 (19) 15 (22) 0.7
Coronary angiographic characteristics
Number of diseased vessels
1 30 (41) 37 (54)
2 33 (45) 22 (32) 0.3
3 10 (14) 9 (13)
TIMI flow after PCI
0–2 4 (5) 4 (6) 1.0
3 69 (95) 64 (93)
Complete revascularisation 51 (70) 54 (78) 0.3
PCI characteristics
No PCI performed 0 (0) 1 (1)
Culprit lesions PCI 73 (100) 68 (99) 0.5
Multiple lesions treated 21 (29) 16 (23) 0.4
Data are expressed as number (%) unless stated otherwise.
SD standard deviation, CAD coronary artery disease, MI myocardial 
infarction, PCI percutaneous coronary intervention, CABG coronary 
artery bypass graft, CHF congestive heart failure, IHD ischaemic 
heart disease.
Fig. 1 The reasons for (late) angiographic exclusion (n = 109) were: 
no significant CAD: n = 55, CABG: n = 27, instent restenosis: n = 9, 
clinically driven immediate PCI n = 8, culprit lesion not amenable to 
PCI: n = 6: chronic total occlusion: n = 4
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flows at initial coronary angiogram were randomised [3]. The 
OPTIMA trial showed an increased rate of periprocedural 
MI in patients treated with immediate PCI. Most PCI-related 
infarcts were small, with little impact on myocardial function, 
and probably resulted from micro-emboli from the athero-
sclerotic plaque or disrupted thrombus particles, or formed 
during angioplasty or thrombotic side branch occlusions [15].
In order to decide the best treatment strategy for patients 
presenting with NSTE-ACS, long-term outcomes are essen-
tial. The long-term follow-up of the OPTIMA trial suggests an 
increased risk of spontaneous MI in those patients treated with 
an immediate PCI for their index NSTE-ACS. The long-term 
results show that half of the culprit lesions for spontaneous 
MI in the immediate group occurred within the index vessel. 
While the increase in re-infarction is -at least partly- explained 
by events originating from the index vessel, one could hypoth-
esise a causal relationship between the timing of PCI during 
an acute event and the risk of a re-infarction later on.
For example, the increase in general coronary vascular 
tone that is often observed during an acute event could ham-
per the proper sizing of the stent. Incorrect sizing could lead 
to an increased risk of malpositioning and eventually cause 
a late ischaemic event [16]. Moreover, immediate PCI might 
have a higher risk of stenting non-significant lesions, due to 
overestimation of lesion severity in the very acute setting. 
Functional tests such as fractional flow reserve to assess the 
clinical significance of coronary artery stenosis of moder-
ate/borderline severity do improve differentiation but were 
NSTE-ACS represents 75 % of all ACS. It has been dem-
onstrated that routine angiography and revascularisation 
after NSTE-ACS reduces mortality by 25 %, MI by 18 %, 
and re-hospitalisation for unstable angina by 31 % at mid-
term follow-up [8].
In the past years, several studies have evaluated the influ-
ence of the timing of intervention in patients with NSTE-
ACS. However, comparison of data and interpretation of the 
results remain difficult due to methodological differences 
between the studies [9–14].
The OPTIMA trial is the only trial that has actually ran-
domised the timing of administering PCI instead of the tim-
ing of angiography. This approach is the only proper way to 
evaluate the influence of time on PCI outcome. However, it 
could be remarked that randomisation after an angiography 
could lead to bias in the selection of patients. As such, during 
the OPTIMA trial, great care was taken to include interme-
diate to high-risk patients and not to select on angiographic 
features. Arguably, a large number of patients with low TIMI 
Table 2 Study endpoints at 5-year follow-up
Immediate 
n = 73 (%)
Deferred 
n = 69 (%)
HR (CI) p-value
Death or sponta-
neous MI
13 (17.8) 7 (10.1) 1.76 
(0.73–4.22)
0.2
Death 6 (8.2) 6 (8.7) 0.90 
(0.29–2.80)
0.9
Spontaneous MI 8 (11) 1 (1.4) 4.46 
(1.21–16.5)
0.02
Re-PCI 5 (6.8) 8 (11.6) 0.53 
(0.18–1.59)
0.3
Composite endpoint and individual endpoints.
MI myocardial infarction, PCI percutaneous coronary intervention, 
HR hazard ratio.
Table 3 Characteristics of spontaneous myocardial infarction
Previous 
CABG
Index vessel 
Non-instent
Index ves-
sel Instent 
restenosis
Spontaneous 
MI non index 
vessel related
Immediate 
n = 8
2 2 2 4
Deferred 
n = 1
– – 1 –
Location of spontaneous myocardial infarction culprit lesion with 
respect to original region of interest during study index coronary 
catheterisation (and PCI).
MI myocardial infarction, CABG coronary artery bypass graft.
Fig. 3 Event rate filtered for the index myocardial infarction (MI) dur-
ing hospitalisation is shown in the main figure. Event rate of first 30 
days of follow-up are presented on the right side. HR hazard ratio
 
Fig. 2 All-cause death (94 % follow-up rate)
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up. As such, the study was too underpowered to detect a 
difference in the clinical event rate at 5 years.
Conclusion
The OPTIMA trial showed a higher incidence of periproce-
dural MI in NSTE-ACS patients treated with immediate PCI, 
as opposed to a ‘wait a day’ approach. Long-term follow-up 
showed no difference in mortality. However, the immediate 
strategy seems to be accompanied by an increased risk of late 
spontaneous MI as well. The exact mechanisms by which this 
excess is caused are currently unknown, but are most likely 
multifactorial in origin. Given the low numbers of total recur-
rent ischaemic events, these findings should be interpreted as 
hypothesis-generating. More long-term follow-up data of ear-
lier and larger trials that randomised to timing of angiography 
in NSTE-ACS are eagerly sought after.
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